Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma
European Journal of Nuclear Medicine and Molecular Imaging · 2023-08 · 50 (10) · 3116-3125
DOI: 10.1007/s00259-023-06248-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 29.05.2023. Verfasst von Wenjia Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College …. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Carbonic Anhydrases. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Chinese Academy of Medical Sciences Initiative for Innovative Medicine, National Natural Science Foundation of China, National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
PURPOSE: Clear cell renal cell carcinoma (ccRCC) highly expresses carbonic anhydrase IX (CAIX). The purpose of this study was to evaluate 68Ga-NY104, a small-molecule CAIX-targeting PET agent, in tumor models of ccRCC and patients diagnosed with confirmed, or suspicious, ccRCC. METHODS: The in vivo and ex vivo biodistribution of 68Ga-NY104 was investigated in CAIX-positive OS-RC-2 xenograft-bearing models. The binding of the tracer was further validated using autoradiography for human ccRCC samples. In addition, three patients with confirmed or suspicious ccRCC were studied. RESULTS: NY104 can be labeled with high radiochemical yield and purity. It quickly cleared through kidney with α-half-life of 0.15 h. Discernible uptake is noted in the heart, lung, liver, stomach, and kidney. The OS-RC-2 xenograft demonstrated intense uptake 5 min after injection and gradually increased until 3 h after injection with ID%/g of 29.29 ± 6.82. Significant binding was detected using autoradiography on sections of human ccRCC tumor. In the three patients studied, 68Ga-NY104 was well-tolerated and no adverse events were reported. Substantial accumulation was observed in both primary and metastatic lesions in patient 1 and 2 with SUVmax of 42.3. Uptake in the stomach, pancreas, intestine, and choroid plexus was noted. The lesion in third patient was correctly diagnosed as non-metastatic for negative 68Ga-NY104 uptake. CONCLUSION: 68Ga-NY104 can efficiently and specifically bind to CAIX. Given the pilot nature of our study, future clinical studies are warranted to evaluate 68Ga-NY104 for detection of CAIX-positive lesions in patients with ccRCC. TRIAL REGISTRATION: The clinical evaluation part of this study was retrospectively registered at ClinicalTrial.gov (NCT05728515) as NYPILOT on 6 Feb, 2023.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical…
- Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
- Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
- Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. zhangyushi@126.com.
ORCID-Profile: Li Huo
Förderung
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine
- National Natural Science Foundation of China
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Zhu, W., Li, X., Zheng, G., Bai, C., Ji, Z., Zhang, H., Xing, H., Zhang, Y., & Huo, L. (2023). Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 50(10), 3116-3125. https://doi.org/10.1007/s00259-023-06248-7
Vancouver
Zhu W, Li X, Zheng G, Bai C, Ji Z, Zhang H, et al. Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 2023;50(10):3116-3125. doi:10.1007/s00259-023-06248-7
BibTeX
@article{Zhu2023,
author = {Zhu, Wenjia and Li, Xiaoyuan and Zheng, Guoyang and Bai, Chunmei and Ji, Zhigang and Zhang, Haiqiong and Xing, Haiqun and Zhang, Yushi and Huo, Li},
title = {Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2023},
volume = {50},
number = {10},
pages = {3116--3125},
doi = {10.1007/s00259-023-06248-7}
}
EUVIMED